LARIMAR THERAPEUTICS, INC.
Income Statement
| Line Item | Mar 2020 | Dec 2019 | Sep 2019 | Jun 2019 | Mar 2019 | Dec 2018 | Sep 2018 | Jun 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $5.0M | $-3.0K | $8.0M | $3.1M | $9.6M | $11.5M | $11.8M | $12.2M |
| SG&A Expense | $1.7M | $-2.4M | $594.0K | $576.0K | $3.6M | $3.2M | $3.3M | $3.4M |
| Operating Income | $-6.7M | $2.4M | $-8.6M | $-3.7M | $-13.3M | $-14.7M | $-15.2M | $-15.6M |
| Operating Margin | — | — | — | — | — | — | — | — |
| Interest Expense | $301.0K | $362.0K | $426.0K | $478.0K | $500.0K | $499.0K | $475.0K | $466.0K |
| Pretax Income | — | — | — | — | — | — | — | — |
| Income Tax Expense | — | — | — | — | — | — | — | — |
| Net Income | $-6.7M | $-7.3M | $-8.6M | $-3.7M | $-4.7M | $-14.6M | $-15.1M | $-15.8M |
| Net Margin | — | — | — | — | — | — | — | — |
| EPS (Basic) | $-1.10 | $-0.19 | $-1.42 | $-0.61 | $-0.35 | $-0.39 | $-0.41 | $-0.57 |
| EPS (Diluted) | $-1.10 | $-0.19 | $-1.42 | $-0.61 | $-0.35 | $-0.39 | $-0.41 | $-0.57 |
| Shares Outstanding (Basic) | 37.5M | 6.1M | 37.4M | 37.3M | 37.3M | 37.3M | 36.9M | 27.6M |
| Shares Outstanding (Diluted) | 37.5M | 6.1M | 37.4M | 37.3M | 37.3M | 37.3M | 36.9M | 27.6M |
| Dividends Per Share | — | — | — | — | — | — | — | — |